Share this video  

ESMO WCGIC 2022 | Final results from FIGHT-202: pemigatinib for patients with FGFR-mutated advanced cholangiocarcinoma

Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, talks on the final results of the FIGHT-202 trial (NCT02924376) which investigated pemigatinib for patients with advanced, metastatic, or surgically unresectable cholangiocarcinoma who had had at least one unsuccessful previous treatment. The trial looked at the efficacy and safety of pemigatinib in three cohorts of patients. Cohort A included patients with FGFR2 translocation with a documented fusion partner, Cohort B included patients with other FGF or FGFR alterations, and Cohort C included patients with no FGF or FGFR alterations. The primary endpoint of the study was objective response rate (ORR) among patients in Cohort A, which was reported to be 37%. The duration of response was reported to be approximately 9 months, progression free survival (PFS) was approximately 7 months, and overall survival (OS) was 17.5 months. These responses were not as good in Cohorts B and C, with Cohort C achieving an OS of 4 months. This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.

Disclosures

Consulting fees: Roche, Bayer, BMS, EISAI, AstraZeneca, Ipsen, MSD, Sirtex, BTG, Servier, Terumo, Imaging Equipment Ltd (AAA), Böhringer Ingelheim

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Roche, Bayer, BMS,, EISAI, AstraZeneca, Ipsen, MSD, Sirtex, BTG, Servier, Terumo, Imaging Equipment Ltd (AAA), Böhringer Ingelheim

Support for attending meetings and/or travel: Roche, Bayer, BMS

Participation on Advisory Board: Roche, Bayer, BMS, Lilly, EISAI, AstraZeneca, Ipsen, MSD, Sirtex, BTG, Servier, Terumo, Imaging Equipment Ltd (AAA).